Christina Boull, MD, explains how pediatricians can recognize dermatologic conditions in darker skin tones and address pigment changes and treatment gaps.
News|Articles|November 10, 2017
Does pediatric psoriasis increase cancer risk? (VIDEO)
Author(s)Bobby Lazzara, MD
For Contemporary Pediatrics, Dr Bobby Lazzara discusses a large retrospective cohort study published in the Journal of the American Academy of Dermatology that examined whether children with pediatric psoriasis are at increased risk of cancer and discusses 2 caveats to the findings.
Advertisement
For Contemporary Pediatrics, Dr Bobby Lazzara discusses a large retrospective cohort study published in the Journal of the American Academy of Dermatology that examined whether children with pediatric psoriasis are at increased risk of cancer and discusses 2 caveats to the findings.
Advertisement
Related to this article
Christina Boull, MD, shares recommendations for infant skin care, including choosing gentle cleansers, avoiding irritants, and supporting the skin barrier.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.
Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.
Oral icotrokinra kept PASI 90 rates at ≥72% and IGA 0/1 at ≥70% from week 64 to 112 in ICONIC-LEAD, with no new safety signals.
At AAP 2026, Peter Lio, MD, discussed distinguishing allergic and inflammatory skin conditions and when pediatricians should seek specialty care.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FAQ: How should pediatricians manage UTIs under new AAP guidance?
2
Global measles cases in children under 5 up 40% since COVID-19
3
Recognizing skin conditions in children with darker skin tones
4
Tezepelumab sustains EoE remission through 52 weeks
5